Citius pharmaceuticals reports productive fda type c meeting to discuss phase 3 mino-lok® program and pathway to approval

Cranford, n.j. , nov. 25, 2024 /prnewswire/ -- citius pharmaceuticals, inc. (nasdaq: ctxr) ("citius pharma" or the "company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the company held a constructive in-person type c meeting with the u.s. food and drug administration (fda).
CTXR Ratings Summary
CTXR Quant Ranking